These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. ß-arrestin 2 germline knockout does not attenuate opioid respiratory depression. Bachmutsky I; Wei XP; Durand A; Yackle K Elife; 2021 May; 10():. PubMed ID: 34002697 [TBL] [Abstract][Full Text] [Related]
5. Opioid Overdose: Limitations in Naloxone Reversal of Respiratory Depression and Prevention of Cardiac Arrest. van Lemmen M; Florian J; Li Z; van Velzen M; van Dorp E; Niesters M; Sarton E; Olofsen E; van der Schrier R; Strauss DG; Dahan A Anesthesiology; 2023 Sep; 139(3):342-353. PubMed ID: 37402248 [TBL] [Abstract][Full Text] [Related]
6. Countering opioid-induced respiratory depression by non-opioids that are respiratory stimulants. Imam MZ; Kuo A; Smith MT F1000Res; 2020; 9():. PubMed ID: 32089833 [TBL] [Abstract][Full Text] [Related]
7. Low doses of cyclic AMP-phosphodiesterase inhibitors rapidly evoke opioid receptor-mediated thermal hyperalgesia in naïve mice which is converted to prominent analgesia by cotreatment with ultra-low-dose naltrexone. Crain SM; Shen KF Brain Res; 2008 Sep; 1231():16-24. PubMed ID: 18656459 [TBL] [Abstract][Full Text] [Related]
8. Highlights in opioid agonists and antagonists. Lauretti GR Expert Rev Neurother; 2006 Apr; 6(4):613-22. PubMed ID: 16623659 [TBL] [Abstract][Full Text] [Related]
10. Opioid-induced respiratory effects: new data on buprenorphine. Dahan A Palliat Med; 2006; 20 Suppl 1():s3-8. PubMed ID: 16764215 [TBL] [Abstract][Full Text] [Related]
11. Advances in Reversal Strategies of Opioid-induced Respiratory Toxicity. van der Schrier R; Dahan JDC; Boon M; Sarton E; van Velzen M; Niesters M; Dahan A Anesthesiology; 2022 Apr; 136(4):618-632. PubMed ID: 34958670 [TBL] [Abstract][Full Text] [Related]
12. Nociceptin Receptor-Related Agonists as Safe and Non-addictive Analgesics. Ding H; Kiguchi N; Dobbins M; Romero-Sandoval EA; Kishioka S; Ko MC Drugs; 2023 Jun; 83(9):771-793. PubMed ID: 37209211 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of Full µ-Opioid Receptor Agonists is not Impaired by Concomitant Buprenorphine or Mixed Opioid Agonists/Antagonists - Preclinical and Clinical Evidence. van Niel JC; Schneider J; Tzschentke TM Drug Res (Stuttg); 2016 Nov; 66(11):562-570. PubMed ID: 27504867 [TBL] [Abstract][Full Text] [Related]
14. Neuraxial morphine and respiratory depression: finding the right balance. Sultan P; Gutierrez MC; Carvalho B Drugs; 2011 Oct; 71(14):1807-19. PubMed ID: 21942973 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological and genetic manipulations at the µ-opioid receptor reveal arrestin-3 engagement limits analgesic tolerance and does not exacerbate respiratory depression in mice. He L; Gooding SW; Lewis E; Felth LC; Gaur A; Whistler JL Neuropsychopharmacology; 2021 Dec; 46(13):2241-2249. PubMed ID: 34257415 [TBL] [Abstract][Full Text] [Related]
17. Non-analgesic effects of opioids: management of opioid-induced constipation by peripheral opioid receptor antagonists: prevention or withdrawal? Holzer P Curr Pharm Des; 2012; 18(37):6010-20. PubMed ID: 22747544 [TBL] [Abstract][Full Text] [Related]
18. Incidence, Reversal, and Prevention of Opioid-induced Respiratory Depression. Dahan A; Aarts L; Smith TW Anesthesiology; 2010 Jan; 112(1):226-38. PubMed ID: 20010421 [TBL] [Abstract][Full Text] [Related]
19. Opioid-induced respiratory depression in humans: a review of pharmacokinetic-pharmacodynamic modelling of reversal. Algera MH; Kamp J; van der Schrier R; van Velzen M; Niesters M; Aarts L; Dahan A; Olofsen E Br J Anaesth; 2019 Jun; 122(6):e168-e179. PubMed ID: 30915997 [TBL] [Abstract][Full Text] [Related]
20. Pharmacological strategy for overcoming opioid-induced ventilatory disturbances. Kimura S; Haji A Eur J Pharmacol; 2014 Feb; 725():87-90. PubMed ID: 23993949 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]